- Stocks
- Healthcare
- NASDAQ: DNLI

Price (delayed)

$19.78

Market cap

$2.75B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.06

Enterprise value

$2.67B

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing

Denali Therapeutics's debt has decreased by 17% from the previous quarter and by 15% YoY

The EPS has soared by 59% YoY but it has decreased by 14% from the previous quarter

The net income has soared by 55% year-on-year but it is down by 17% since the previous quarter

The quick ratio has declined by 15% since the previous quarter

Denali Therapeutics's equity has decreased by 8% QoQ

What are the main financial stats of DNLI

Market
Valuations
Earnings

Shares outstanding

139.16M

Market cap

$2.75B

Enterprise value

$2.67B

Price to earnings (P/E)

N/A

Price to book (P/B)

2.65

Price to sales (P/S)

8.22

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

8.08

Revenue

$330.53M

EBIT

-$145.19M

EBITDA

-$128.47M

Free cash flow

-$370.93M

Per share
Balance sheet
Liquidity

EPS

-$1.06

Free cash flow per share

-$2.7

Book value per share

$7.46

Revenue per share

$2.41

TBVPS

$8.4

Total assets

$1.15B

Total liabilities

$122.96M

Debt

$44.98M

Equity

$1.03B

Working capital

$986.16M

Debt to equity

0.04

Current ratio

13.65

Quick ratio

13.27

Net debt/EBITDA

0.64

Margins
Efficiency
Dividend

EBITDA margin

-38.9%

Gross margin

100%

Net margin

-43.9%

Operating margin

-59.5%

Return on assets

-11.4%

Return on equity

-13.5%

Return on invested capital

-13.7%

Return on capital employed

-13.5%

Return on sales

-43.9%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Denali Therapeutics stock price performed over time

Intraday

-2.13%

1 week

17.53%

1 month

12.9%

1 year

-27.15%

YTD

-7.83%

QTD

-7.83%

How have Denali Therapeutics's revenue and profit performed over time

Revenue

$330.53M

Gross profit

$330.53M

Operating income

-$196.7M

Net income

-$145.22M

Gross margin

100%

Net margin

-43.9%

Denali Therapeutics's net margin has soared by 85% YoY but it has decreased by 20% from the previous quarter

DNLI's operating margin has surged by 81% year-on-year but it is down by 20% since the previous quarter

The net income has soared by 55% year-on-year but it is down by 17% since the previous quarter

DNLI's operating income is up by 42% year-on-year but it is down by 16% since the previous quarter

What is Denali Therapeutics's growth rate over time

What is Denali Therapeutics stock price valuation

P/E

N/A

P/B

2.65

P/S

8.22

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

8.08

The EPS has soared by 59% YoY but it has decreased by 14% from the previous quarter

DNLI's price to book (P/B) is 44% less than its 5-year quarterly average of 4.7 and 12% less than its last 4 quarters average of 3.0

Denali Therapeutics's equity has decreased by 8% QoQ

The stock's price to sales (P/S) is 80% less than its 5-year quarterly average of 42.0 and 45% less than its last 4 quarters average of 15.0

DNLI's revenue is down by 3% since the previous quarter

How efficient is Denali Therapeutics business performance

The ROS has soared by 85% YoY but it has decreased by 20% from the previous quarter

The return on invested capital has surged by 63% year-on-year but it has declined by 15% since the previous quarter

The return on equity has surged by 62% year-on-year but it has declined by 17% since the previous quarter

The return on assets has surged by 54% year-on-year but it has declined by 24% since the previous quarter

What is DNLI's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for DNLI.

How did Denali Therapeutics financials performed over time

DNLI's total liabilities has dropped by 71% year-on-year but it is up by 3.8% since the previous quarter

The company's total assets fell by 21% YoY and by 7% QoQ

Denali Therapeutics's debt is 96% less than its equity

DNLI's debt to equity is down by 20% since the previous quarter and by 20% year-on-year

Denali Therapeutics's debt has decreased by 17% from the previous quarter and by 15% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.